DNA Programmed Macrocycle Discovery - IDO Inhibitor program
John Ripple
CEO, Ensemble Therapeutics
Using our DNA-programmed library platform, Ensemble has recently identified novel, potent and highly selective macrocyclic inhibitors of IDO, which bind outside of the active site. The compounds are currently in preclinical development.